CLINICAL RESEARCH: ISCHEMIC PRECONDITIONING
Caffeine Prevents Protection in Two Human Models of Ischemic Preconditioning
Niels P. Riksen, MD*, ,*,
Zhigang Zhou, MD*,
Wim J.G. Oyen, MD, PhD ,
Rogier Jaspers, MD ,
Bart P. Ramakers, MSc*,
Rene M.H.J. Brouwer, MD, PhD,
Otto C. Boerman, PhD,
Neil Steinmetz, MD, PhD||,
Paul Smits, MD, PhD*, and
Gerard A. Rongen, MD, PhD*,
* Pharmacology-Toxicology
Internal Medicine
Nuclear Medicine
Cardiothoracic Surgery, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands
|| North American Scientific, Theseus Imaging Division, Boston, Massachusetts
Manuscript received February 15, 2006;
revised manuscript received April 4, 2006,
accepted April 10, 2006.
* Reprint requests and correspondence: Dr. Niels P. Riksen, Department of Pharmacology-Toxicology 149, Radboud University Nijmegen Medical Center, Geert Grooteplein 21, 6525 EZ Nijmegen, the Netherlands. (Email: N.Riksen{at}aig.umcn.nl).
OBJECTIVES: We studied whether caffeine impairs protection by ischemic preconditioning (IP) in humans.
BACKGROUND: Ischemic preconditioning is critically dependent on adenosine receptor stimulation. We hypothesize that the adenosine receptor antagonist caffeine blocks the protective effect of IP.
METHODS: In vivo ischemia-reperfusion injury was assessed in the thenar muscle by 99mTc-annexin A5 scintigraphy. Forty-two healthy volunteers performed forearm ischemic exercise. In 24 subjects, this was preceded by a stimulus for IP. In a randomized double-blinded design, the subjects received caffeine (4 mg/kg) or saline intravenously before the experiment. At reperfusion, 99mTc-annexin A5 was administered intravenously. Targeting of annexin was quantified by region-of-interest analysis, and expressed as percentage difference between experimental and contralateral hand. In vitro, we assessed recovery of contractile function of human atrial trabeculae, harvested during heart surgery, as functional end point of ischemia-reperfusion injury. Field-stimulated contraction was quantified at baseline and after simulated ischemia-reperfusion, in a paired approach with and without 5 min of IP, in the presence (n = 13) or absence (n = 17) of caffeine (10 mg/l).
RESULTS: Ischemic preconditioning reduced annexin targeting in the absence of caffeine (from 13 ± 3% to 7 ± 1% at 1 h, and from 19 ± 2% to 9 ± 3% at 4 h after reperfusion, p = 0.006), but not after caffeine administration (targeting 11 ± 2% and 16 ± 3% at 1 and 4 h). In vitro, IP improved post-ischemic functional recovery in the control group, but not in the caffeine group (8 ± 3% vs. –8 ± 5%, p = 0.003).
CONCLUSIONS: Caffeine abolishes IP in 2 human models at a dose equivalent to the drinking of 2 to 4 cups of coffee. (The Effect of Caffeine on Ischemic Preconditioning; http://clinicaltrials.gov/ct/show/NCT00184912?order=1; NCT00184912
[ClinicalTrials.gov]
).
|
Abbreviations and Acronyms
| | IP = ischemic preconditioning | | Isch Ex = ischemic exercise |
|
This article has been cited by other articles:
|
|
|
|
 
C. R. Frasier, R. L. Moore, and D. A. Brown
Exercise-induced cardiac preconditioning: how exercise protects your achy-breaky heart
J Appl Physiol,
September 1, 2011;
111(3):
905 - 915.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. B. Fredholm, A. P. IJzerman, K. A. Jacobson, J. Linden, and C. E. Muller
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors--An Update
Pharmacol. Rev.,
March 1, 2011;
63(1):
1 - 34.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Mostofsky, G. Schlaug, K. J. Mukamal, W. D. Rosamond, and M. A. Mittleman
Coffee and acute ischemic stroke onset: The Stroke Onset Study
Neurology,
November 2, 2010;
75(18):
1583 - 1588.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Niccoli, R. K. Kharbanda, F. Crea, and A. P. Banning
No-reflow: again prevention is better than treatment
Eur. Heart J.,
October 2, 2010;
31(20):
2449 - 2455.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Draisma, M. de Goeij, C. W. Wouters, N. P. Riksen, W. J.G. Oyen, G. A. Rongen, O. C. Boerman, M. van Deuren, J. G. van der Hoeven, and P. Pickkers
Endotoxin tolerance does not limit mild ischemia-reperfusion injury in humans in vivo
Innate Immunity,
December 1, 2009;
15(6):
360 - 367.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. G. Blankenberg
Imaging the Molecular Signatures of Apoptosis and Injury with Radiolabeled Annexin V
Proceedings of the ATS,
August 15, 2009;
6(5):
469 - 476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Meijer, W. J.G. Oyen, D. Dekker, P. H.H. van den Broek, C. W. Wouters, O. C. Boerman, G. J. Scheffer, P. Smits, and G. A. Rongen
Rosuvastatin Increases Extracellular Adenosine Formation in Humans In Vivo: A New Perspective on Cardiovascular Protection
Arterioscler Thromb Vasc Biol,
June 1, 2009;
29(6):
963 - 968.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Peart and J. P. Headrick
Clinical cardioprotection and the value of conditioning responses
Am J Physiol Heart Circ Physiol,
June 1, 2009;
296(6):
H1705 - H1720.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. G. Blankenberg
In Vivo Detection of Apoptosis
J. Nucl. Med.,
June 1, 2008;
49(Suppl_2):
81S - 95S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. P. Riksen, B. Franke, W. J.G. Oyen, G. F. Borm, P. van den Broek, O. C. Boerman, P. Smits, and G. A. Rongen
Augmented hyperaemia and reduced tissue injury in response to ischaemia in subjects with the 34C > T variant of the AMPD1 gene
Eur. Heart J.,
May 1, 2007;
28(9):
1085 - 1091.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
